Yonezawa H et al., 2022-03: Biochemical study using immobilised ivermectin B1a affinity purification that identifies TELO2, a PIKK cofactor, as a direct ivermectin-binding protein and links it to the reduction of cytoplasmic beta-catenin and beta-catenin/TCF transcriptional activity.
Therefore, IVM binds to TELO2, inhibiting PIKKs and reducing the cytoplasmic β-catenin level.
n/a (HTML full text)
Yonezawa H et al., 2022-03: Biochemical study using immobilised ivermectin B1a affinity purification that identifies TELO2, a PIKK cofactor, as a direct ivermectin-binding protein and links it to the reduction of cytoplasmic beta-catenin and beta-catenin/TCF transcriptional activity. Study type: in vitro biochemistry/cell line (binding, knockdown, mutagenesis). N: n/a. Country: Japan (Tohoku University affiliation per record). Dose: in vitro concentrations, not stated in the abstract. Funder: not stated in the retrieved record. Declared COI: 'The authors declare no competing interests.' Comparator: TELO2 knockdown and mutant TELO2. This is a later mechanistic confirmation of the Melotti WNT-TCF finding, via a different proposed target. Study type: lab.
